Type i NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma

Blood

Volumn 111, Issue 12, 2008, Pages 5637-5645

  Renukaradhya, Gourapura J ^a,b,c   Khan, Masood A ^a,b,c   Vieira, Marcus ^a,b,c   Du, Wenjun ^d   Gervay Hague, Jacquelyn ^d   Brutkiewicz, Randy R ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTHER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD1D ANTIGEN; CYTOKINE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BAGG ALBINO MOUSE; BONE MARROW CELL; CELL FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; INBRED STRAIN; INNATE IMMUNITY; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER T CELL; NATURAL KILLER T CELL TYPE I; NATURAL KILLER T CELL TYPE II; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ADOPTIVE TRANSFER; ANIMAL; ASCITES; CYTOLOGY; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; MORTALITY; MOUSE MUTANT; NATURAL KILLER CELL; SPLEEN; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ASCITES; CELL LINE, TUMOR; CYTOKINES; FEMALE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID CELLS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS;

EID: 47049090132     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-05-092866     Document Type: Article

References (55)

1. Shukla NISI, Trippett TM. Non-Hodgkin's lymphoma in children and adolescents. Curr Oncol Rep. 2006:8:387-394.
2. Smyth MJ, Godfrey Dl. NKT cells and tumor immunity-a double-edged sword. Nat Immunol. 2000;1:459-460.
3. Brutkiewicz RR. CD1d ligands: the good, the bad, and the ugly. J Immunol. 2006;177:769-775.
4. Seino K. Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. Natural killerT cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 2006;97:807-812.
5. Berzins SR Smyth MJ, Godfrey Dl. Working with NKT cells-pitfalls and practicalities. Curr Opin Immunol. 2005;17:448-454.
6. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med. 2005;202: 1623-1626.
7. Brutkiewicz RR, Lin Y, Cho S, Hwang YK, Shram V, Roberts TJ. CD1d-mediated antigen presentation to natural killer T (NKT) cells. Crit Rev Immunol. 2003;23:403-419.
8. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity. 1997;6:469-477.
9. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveil- lance by IL-13 and the IL-4-STAT6 pathway. Nat Immunol. 2000;1:515-520.
10. Terabe M, Swann J, Ambrosino E. et al. Anon- classical non-Vα14Jα18 CD1 d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005;202:1627-1633.
11. Renukaradhya GJ; Shram V Du W; Gervay- Hague J, Van Kaer L, Brutkiewicz RR. Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer. 2006;118:3045-3053.
12. Metelitsa LS, Weinberg Kl, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leu- kemias provides a target for cytotoxic NKT cells. Leukemia. 2003;17:1068-1077.
13. + T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci USA. 2002;99:8197-8202.
14. Haraguchi K, Takahashi T Nakahara F etal. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma. 2006;47:2218-2223.
15. Serafini P, De Santo C, Marigo L et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004;53: 64-72.
16. Yang L, DeBusk LM. Fukuda K. et al. Expansion of myeloid immune suppressor Gr+CD11 b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409-421.
17. Yanagisawa K, Exley MA, Jiang X, Ohkochi N, Taniguchi M, Seino K. Hyporesponsiveness to natural killer T-cell ligand α-galactosylceramide in cancer-bearing state mediated by CD11 b+ Gr-1 4- cells producing nitric oxide. Gancer Res. 2006;66:11441-11446.
18. Cui J, ShinT KawanoT et al. Requirement tor Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623-1626.
19. Roberts TJ, Shram V, Spence PM; et al. Recycling CD1 d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol. 2002;168:5409-5414.
20. Shram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomo-nas paucimobilis are CD1 d-specitic ligands tor NKT cells. Eur J Immunol. 2005:35:1692-1701.
21. Hobbs JA, Cho S, Roberts TJ, et al. Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J Virol. 2001 ;75:10746-10754.
22. + T lymphocytes. Science. 1995;268: 863-865.
23. - T cells in mice and humans. J Exp Med. 1994;180:1097-1106.
24. Brutkiewicz RR. Klaus SJ, Welsh RM. Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression. Nat Immun. 1992;11:203-214.
25. Porcelli SA, Modlin RL. The CD1 System: Antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol. 1999;17:297-329.
26. Carnaud C, Lee D, Donnars O, et al. Gutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163:4647-4650.
27. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol. 2000;30:985-992.
28. Brutkiewicz RR, Shram V. Natural killer T (NKT) cells and their role in antitumor immunity. Grit Rev Oncol Hematol. 2002;41:287-298.
29. Ljunggren HG, Karre K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244.
30. Crowe NY, Coquet JM, Berzins SP, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med. 2005;202:1279-1288.
31. Stewart TJ. Smyth MJ, Fernando GJ, Frazer IH. Leggatt GR. Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells. Cancer Res. 2003;63:3058-3060.
32. Terabe M. Matsui S, Park JM, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1 d-restricted T cells block cytotoxic T lymphocyte- mediated tumor imrnunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003;198: 1741-1752.
33. Smyth MJ, Taniguchi M, Street SE. The antitumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000;165:2665-2670.
34. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
35. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336.
36. + natural Tcells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol. 1999;163:2314-2321.
37. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1 d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195:625-636.
38. Karadimitris A, Gadola S, Altamirano M, et al. Human GD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci USA. 2001 ;98:3294-3298.
39. Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer Tcells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 2002;123: 1031-1043.
40. Lee PT, Benlagha K, Teyton L, BendelacA. Distinct functional lineages of human Vα24 natural killer Tcells. J Exp Med. 2002;195:637-641.
41. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and antiinflammatory functions of different subsets of CD Id-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun. 2005; 73:181-192.
42. Mallevaey T, Fontaine J, Breuilh L. et al. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis. Infect Immun. 2007;75:2171-2180.
43. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675-678.
44. Farag SS, Caligiuri MA. Immunologic approaches to acute leukemia in the elderly. Semin Hematol. 2006;43:118-125.
45. Smyth MJ, Thia KYT. Street SEA, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191:661-668.
46. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey Dl, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med. 2005;201: 1973-1985.
47. Haider RC; Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest. 2007;117:2302-2312.
48. Kato T Kaneko S, Kimizuka R, Okuda K. Peri-odontopathic bacterial endotoxin-induced tumor necrosis factor a production was inhibited by exercise in mice. FEMS Immunol Med Microbiol. 2006;47:262-266.
49. Dhodapkar MV, Geller MD, Chang DH. et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003; 197:1667-1676.
50. Dhodapkar KM, Cirignano B, Chamian F et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer. 2004;109:893-899.
51. Wu DY Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialogan-glioside GD3 to natural killer T Gells. J Exp Med. 2003;198:173-181.
52. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med. 2007;204: 2641-2653.
53. Yasunami Y, Kojo S, Kitamura H, et al. Va14 NK T cell-triggered IFN-γ production by Gr-1 + CD11 b + cells mediates early graft loss of syngeneic transplanted islets. J Exp Med. 2005;202: 913-918.
54. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis. 2003;20:195-201.
55. Kofler DM, Mayr C, Wendtner CM. Current status of immunotherapy in B cell malignancies. Gurr Drug Targets. 2006;7:1371-1374.